CD274 and non-small cell lung carcinoma: In the earliest studies in which most regimens are now considered to be second-line and above, patients with advanced non-squamous (CheckMate 057) or squamous cell (CheckMate 017) NSCLC previously treated with chemotherapy had better overall survival (OS) or progression-free survival (PFS) with nivolumab than with docetaxel, regardless of PD-L1 expression level (7, 8).